Caplin Point Laboratories Limited Q1 FY27 results deck summary

Results deck of 12 Aug 2026, summarised by AI from the filing.

Q1 FY27 total revenue ₹643.91 cr, up 20.7% YoY, with PAT ₹179.09 cr, up 18.8% YoY.

Key takeaways

1. Capex guidance Enhanced capex budget of approximately ₹1000+ cr, with around 50% nearing completion and balance over next 2-3 years.
2. US growth US market Q1 FY27 total revenue ₹137 cr, up 26% YoY.
3. Emerging markets Won emergency tenders in Central America worth $7 million and Chile tenders worth $12 million.
4. Gross margin Gross margin declined to 59.8% in Q1 FY27 from 61.7% in Q1 FY26.

Original filing on BSE

Caplin Point Laboratories Limited Q1 FY27 results

As filed: Revenue ₹610 cr (+20% year on year), EBITDA ₹213 cr (+21% year on year), PAT ₹179 cr (+19% year on year), EBITDA margin 35.0% (+27 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹600 cr (+20% year on year), EBITDA ₹204 cr (+22% year on year), PAT ₹173 cr (+19% year on year), EBITDA margin 34.0% (+56 bps). Score 70 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin rose 56 bps year on year. Revenue rose ₹98.2 cr on a year ago, more than the ₹49.0 cr it added the year before. Share price after the results: +30.7% in 29 days (Nifty 500: +1.0%).
• Q3 FY26: Revenue ₹543 cr (+10% year on year), EBITDA ₹190 cr (+17% year on year), PAT ₹166 cr (+18% year on year), EBITDA margin 35.0% (+209 bps). Score 59 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 209 bps year on year. Revenue rose ₹49.8 cr on a year ago, against ₹57.0 cr the year before. Share price after the results: −12.8% in 29 days (Nifty 500: −4.5%).
• Q2 FY26: Revenue ₹534 cr (+11% year on year), EBITDA ₹189 cr (+15% year on year), PAT ₹160 cr (+22% year on year), EBITDA margin 35.4% (+123 bps). Score 53 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was above it. EBITDA margin rose 123 bps year on year. Revenue rose ₹51.0 cr on a year ago, against ₹73.0 cr the year before. Share price after the results: −1.6% in 30 days (Nifty 500: +0.7%).
• Q1 FY26: Revenue ₹510 cr (+11% year on year), EBITDA ₹177 cr (+17% year on year), PAT ₹151 cr (+21% year on year), EBITDA margin 34.7% (+181 bps). Score 52 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was above it. EBITDA margin rose 181 bps year on year. Revenue rose ₹51.0 cr on a year ago, against ₹64.0 cr the year before. Share price after the results: +10.8% in 29 days (Nifty 500: +0.7%).
• Q4 FY25: Revenue ₹502 cr (+11% year on year), EBITDA ₹168 cr (+16% year on year), PAT ₹145 cr (+20% year on year), EBITDA margin 33.5% (+146 bps). Score 51 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin rose 146 bps year on year. Revenue rose ₹49.0 cr on a year ago, against ₹64.0 cr the year before. Share price after the results: +6.2% in 29 days (Nifty 500: +1.8%).
• Q3 FY25: Revenue ₹493 cr (+13% year on year), EBITDA ₹162 cr (+14% year on year), PAT ₹140 cr (+17% year on year), EBITDA margin 32.9% (+29 bps). Score 39 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 29 bps year on year. Revenue rose ₹57.0 cr on a year ago, against ₹64.0 cr the year before.
• Q2 FY25: Revenue ₹483 cr (+18% year on year), EBITDA ₹165 cr (+20% year on year), PAT ₹131 cr (+13% year on year), EBITDA margin 34.2% (+50 bps). Score 60 of 100, In line with trend. EBITDA margin rose 50 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Caplin Point Laboratories Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (12 Aug 2026)
• Q3 FY26: Results deck (5 Feb 2026)